Gemigliptin
| Evidence Level: L5 | Predicted Indications: 4 |
Table of Contents
Gemigliptin: From Type 2 Diabetes Mellitus to Opsismodysplasia
One-Sentence Summary
Gemigliptin is a DPP-4 inhibitor originally used to treat type 2 diabetes mellitus. The TxGNN model predicts it may be effective for Opsismodysplasia, a rare skeletal dysplasia, but there are currently no clinical trials and no publications supporting this prediction. It rests on the model’s prediction alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Type 2 diabetes mellitus |
| Predicted New Indication | Opsismodysplasia |
| TxGNN Prediction Score | 0.9932 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (1 of 1) – CDSCO approval status is not included in this data |
| Number of Listed Products | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Gemigliptin is generally known as a DPP-4 inhibitor, a class that raises incretin levels (GLP-1 and GIP) and improves blood sugar control in type 2 diabetes.
Opsismodysplasia is a rare skeletal disorder caused by INPPL1 mutations (loss of SHIP2 function), which affect PI3K/AKT signalling and the formation of bone from cartilage. No known pathway links DPP-4 inhibition to INPPL1/SHIP2 biology or to growth plate defects. The high TxGNN score is a model-based prediction only, and no mechanistic explanation currently supports it.
Other top-ranked predictions have the same weakness: thiamine-responsive dysfunction syndrome (0.9928), focal stiff limb syndrome (0.9926) and classic stiff person syndrome (0.9926) all have high TxGNN scores, yet none has trials, publications or an established mechanistic link. For the two stiff-person-spectrum conditions, DPP-4 (CD26) is expressed on T cells and may have a speculative immunomodulatory role, but this is unsupported.
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Registration No. 247491 | Zemiglo 50mg Tablet (Sanofi India Ltd) | Strip of 14 tablets (oral) | Not specified in the available data |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no clinical trials, no literature and no plausible mechanistic link. It remains at the model-prediction-only stage (L5). Safety and mechanism data are also incomplete.
To proceed, the following is needed:
- Mechanism of action data for gemigliptin, and a biological rationale connecting DPP-4 inhibition to INPPL1/SHIP2 signalling or skeletal development
- The India package insert (warnings, contraindications and approved indication text)
- Preclinical or in vitro evidence supporting any effect in opsismodysplasia
- A literature and trial search to confirm no relevant studies exist
- A comparison of the top-ranked predictions to see whether any has a more credible mechanistic or clinical rationale
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.